|
1.
|
|
|
2.
|
|
8 p, 2.9 MB |
Antagonism of miR-148a attenuates atherosclerosis progression in APOBTGApobec-/-Ldlr+/- mice : A brief report
/
Rotllan, Noemi (Institut d'Investigació Biomèdica Sant Pau) ;
Zhang, X. (Yale University School of Medicine) ;
Canfrán-Duque, A. (Yale University School of Medicine) ;
Goedeke, L. (Yale University School of Medicine) ;
Griñán, Raquel (Institut d'Investigació Biomèdica Sant Pau) ;
Ramírez, C.M. (IMDEA Research Institute of Food and Health Sciences) ;
Suárez, Y. (Yale University School of Medicine) ;
Fernández-Hernando, C. (Yale University School of Medicine) ;
Universitat Autònoma de Barcelona
miR-148a-3p (miR-148a) is a hepatic and immune-enriched microRNA (miRNA) that regulates macrophage-related lipoprotein metabolism, cholesterol homeostasis, and inflammation. The contribution of miR-148a-3p to the progression of atherosclerosis is unknown. [...]
2022 -  10.1016/j.biopha.2022.113419
Biomedicine & pharmacotherapy, Vol. 153 (september 2022) , p. 113419
|
|
|
3.
|
|
31 p, 986.9 KB |
Engineering aldo-keto reductase 1B10 to mimic the distinct 1B15 topology and specificity towards inhibitors and substrates, including retinoids and steroids
/
Giménez-Dejoz, Joan (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Weber, Susanne (Research Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum München) ;
Fernández-Pardo, Álvaro (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Möller, Gabriele (Research Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum München) ;
Adamski, Jerzy (Research Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum München) ;
Porté, Sergio (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Parés i Casasampera, Xavier (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Farrés, Jaume (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
The aldo-keto reductase (AKR)superfamily comprises NAD(P)H-dependent enzymes that catalyze the reduction of a variety of carbonyl compounds. AKRs are classified in families and subfamilies. Humans exhibit three members of the AKR1B subfamily: AKR1B1 (aldose reductase, participates in diabetes complications), AKR1B10 (overexpressed in several cancer types), and the recently described AKR1B15. [...]
2019 - 10.1016/j.cbi.2019.04.030
Chemico-Biological Interactions, Vol. 307 (2019) , p. 186-194
|
|
|
4.
|
|
19 p, 876.8 KB |
Advances and Challenges in the Assessment of Executive Functions in Under 36 Months : a Scoping Review
/
Escobar-Ruiz, Valeria (Universitat Autònoma de Barcelona) ;
Arias-Vázquez, Pedro I. (División Académica Multidisciplinaria de Comalcalco. Universidad Juárez Autónoma de Tabasco) ;
Tovilla-Zárate, Carlos A. (División Académica Multidisciplinaria de Comalcalco. Universidad Juárez Autónoma de Tabasco) ;
Doval Dieguez, Eduardo (Universitat Autònoma de Barcelona. Departament de Psicobiologia i de Metodologia de Ciències de la Salut) ;
Jané i Ballabriga, Maria del Claustre (Universitat Autònoma de Barcelona. Departament de Psicologia Clínica i de la Salut)
Objectives: Neurodevelopmental disorders present deficits in executive functions (EFs). Before 36 months old, EFs act as basic abilities that allow adequate executive functioning at later ages. Three basic EFs are assessable before the child reaches 36 months old: working memory, inhibition, and cognitive flexibility. [...]
Objetivos: Los trastornos del neurodesarrollo presentan déficits en las funciones ejecutivas (FE). Antes de los 36 meses, las FE actúan como habilidades básicas que permiten un adecuado funcionamiento ejecutivo en edades posteriores. [...]
2023 - 10.1007/s41252-023-00366-x
Advances in Neurodevelopmental Disorders, 2023
|
|
|
5.
|
|
10 p, 922.8 KB |
The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy : Implications for Complement-Targeted Therapies
/
Querol, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Hartung, Hans-Peter (Palacky University Olomouc) ;
Lewis, Richard A. (Cedars Sinai Medical Center) ;
van Doorn, Pieter A. (University Medical Center) ;
Hammond, Timothy R. (Sanofi) ;
Atassi, Nazem (Sanofi) ;
Alonso-Alonso, Miguel (Sanofi) ;
Dalakas, Marinos C. (Neuroimmunology National and Kapodistrian University of Athens Medical School) ;
Universitat Autònoma de Barcelona
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common, heterogeneous, immune-mediated neuropathy, characterized by predominant demyelination of motor and sensory nerves. CIDP follows a relapsing-remitting or a progressive course and causes substantial disability. [...]
2022 - 10.1007/s13311-022-01221-y
Neurotherapeutics, Vol. 19 Núm. 3 (april 2022) , p. 864-873
|
|
|
6.
|
|
5 p, 3.7 MB |
Decreased activation of parvalbumin interneurons in the medial prefrontal cortex in intact inbred Roman rats with schizophrenia-like reduced sensorimotor gating
/
Tapias-Espinosa, Carles (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Sánchez González, Ana (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Cañete, Toni (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Sampedro-Viana, Daniel (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Castillo-Ruiz, Mª del Mar (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Tobeña, Adolf 1950- (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Oliveras, Ignasi ;
Fernández-Teruel, Alberto (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Aznar, Susana (Research Laboratory for Stereology and Neuroscience, Bispebjerg Copenhagen University Hospital)
Prepulse inhibition (PPI) allows assessing schizophrenia-like sensorimotor gating deficits in rodents. Previous studies indicate that PPI is modulated by the medial prefrontal cortex (mPFC), which is in agreement with our findings showing that PPI differences in the Roman rats are associated with divergences in mPFC activity. [...]
2023 - 10.1016/j.bbr.2022.114113
Behavioural Brain Research, Vol. 437 (Feb. 2023) , art. 114113
|
|
|
7.
|
|
36 p, 1.6 MB |
Schizophrenia-like reduced sensorimotor gating in intact inbred and outbred rats is associated with decreased medial prefrontal cortex activity and volume
/
Tapias-Espinosa, Carles (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Río-Álamos, Cristobal (Universidad Austral de Chile. Departamento de Psicologia) ;
Sánchez González, Ana (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Oliveras, Ignasi (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Sampedro-Viana, Daniel (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Castillo-Ruiz, Mª del Mar (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Cañete, Toni (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Tobeña, Adolf 1950- (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Fernández-Teruel, Alberto (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Prepulse inhibition (PPI) of startle response is a measure of sensorimotor gating that is impaired in schizophrenia and in many other clinical conditions. Rat models using pharmacological or surgical strategies reveal that PPI is modulated by the cortico-striatal-pallido-thalamic (CSPT) circuit. [...]
2019 - 10.1038/s41386-019-0392-x
Neuropsychopharmacology, Vol. 44 Núm. 11 (2019) , p. 1975-1984
Neuropsychopharmacology, 2019
|
|
|
8.
|
|
30 p, 681.2 KB |
Increased exploratory activity in rats with deficient sensorimotor gating: a study of schizophrenia-relevant symptoms with genetically heterogeneous NIH-HS and Roman rat strains
/
Tapias-Espinosa, Carles (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Río-Álamos, Cristobal (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Sampedro-Viana, Daniel (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Gerbolés, Cristina (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Oliveras, Ignasi (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Sánchez González, Ana (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Tobeña, Adolf 1950- (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Fernández-Teruel, Alberto (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Universitat Autònoma de Barcelona.
Institut de Neurociències
Schizophrenia involves positive, negative and cognitive symptoms, as well as comorbidity with anxiety and obsessive-compulsive disorder. Prepulse inhibition (PPI) of the startle response is a measure of sensorimotor gating that is impaired in schizophrenia and animal models of the disease. [...]
2018 - 10.1016/j.beproc.2018.03.019
Behavioural Processes, Vol. 151 (june 2018) , p. 96-103
|
|
|
9.
|
|
|
10.
|
|
12 p, 648.4 KB |
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
/
Bittner, Vera A. (University of Alabama at Birmingham) ;
Szarek, Michael (State University of New York) ;
Aylward, Philip (South Australian Health and Medical Research Institute) ;
Bhatt, Deepak L. (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ;
Díaz, Rafaël J. (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Fras, Zlatko (Univerza V Ljubljani) ;
Goodman, Shaun G. (University of Toronto) ;
Halvorsen, Sigrun (University of Oslo) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Stanford University) ;
Jukema, J. Wouter (Leiden University Medical Center) ;
Loizeau, Virginie (Sanofi) ;
Moriarty, Patrick Maurice (University of Kansas Medical Center) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals Inc.) ;
Roe, Matthew T. (Duke University School of Medicine) ;
Sinnaeve, Peter (University of Leuven) ;
Tsimikas, Sotirios (University of California San Diego) ;
Vogel, Robert A. (University of Colorado School of Medicine) ;
White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ;
Zahger, Doron (Soroka University Medical Center) ;
Zeiher, Andreas Michael (Goethe University) ;
Steg, Philippe Gabriel (Royal Brompton Hospital (Londres)) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Cequier, Ángel (Hospital Universitari de Bellvitge) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). [...]
2020 - 10.1016/j.jacc.2019.10.057
Journal of the American College of Cardiology, Vol. 75 Núm. 2 (21 2020) , p. 133-144
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
